39 Investor presentation First nine months of 2021 Novo Nordisk has a strong leader growing diabetes market Global diabetes market by treatment class 1 DKK billion Novo Nordisk rem value ma 350 Market CAGR 2 : 8.7% 35% 300 30% 250 CAGR: 0.4% 25% 200 20% 150 CAGR: 24.9% 15% 100 10% 50 CAGR: (3.2%) 5% 0 15FY 16FY 17FY 18FY 19FY 20FY Insulin GLP-1 SGLT-2 DPP-4 0% Aug 2011 Novo No Sanofi Merck AstraZen J&J 1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data do 2 CAGR for 5-year period; ; BI: Boehringer Ingelheim; J&J: Johnson & Johnson Source: IQVIA MAT, Aug 2021 value figures Note: IQVIA data can be inflated due to use of list prices in the US
Download PDF file